Our data suggest that pharmacologic modulation of the SUMO pathway with TAK-981 positively regulates HIF-1α in our system, thereby highlighting the potential benefit of using TAK-981 to enhance activity of hydroxylase inhibitors in the treatment of intestinal disorders. The gene discussed is HIF1A; the disease is intestinal disorder.